Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer
Sponsor: 307 Hospital of PLA
A PHASE2 clinical study on ERBB2 Gene Amplification and Neoplasms Metastasis, this trial is completed. The trial is conducted by 307 Hospital of PLA and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 307 Hospital of PLA
- Fudan University
- Nanfang Hospital, Southern Medical University
- Second Affiliated Hospital of Suzhou University
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Shandong Provincial Hospital
- Shandong Tumor Hospital
- Sixth Affiliated Hospital, Sun Yat-sen University
- Sun Yat-sen University
- Tianjin Medical University General Hospital
- Tongji Hospital
- West China Hospital
For direct contact, visit the study record on ClinicalTrials.gov .